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A triglyceride analog, glycerol-2-palmitoyl-1,3-di-15-(p-iodophenyl)pentadecanoate (DPPG) was syn- 
thesized and radiolabeled for evaluation as a potential functional liver scintigraphic agent. Uptake of 
DPPG was compared in normal, diabetic, tumor-bearing and heparin pretreated rats, revealing differences 
in uptake and clearance of radioactivity, correlating with hepatic lipase activity of these groups. Similar 
results were observed by y-camera scintigraphy. Comparing the uptake of DPPG with that of its fatty 
acid component, 1 S-(p-iodophenyl)pentadecanoic acid (IPPA), revealed that the peak uptake of IPPA in 
the liver was about half that of DPPG. Based upon these findings, DPPG warrants further study as a 
hepatic radiodiagnostic agent. 
Introduction 
Currently the two most frequently used types of 
liver radiodiagnostics are the 99mTc-labeled sulfur 
colloid or microaggregated albumin and the 99mTc- 
labeled iminodiacetic acid (IDA) derivatives. The 
99mT~ colloids are phagocytized by the reticuloen- 
dothelial (RE) cells of the liver and spleen. Decreased 
hepatocellular function as in the case of malignant 
melanoma, portal hypotension or cirrhosis causes 
more radioactivity to be taken up by the spleen and 
bone marrow (Jost, 1987). Since the RE cells are 
distributed throughout the liver, scintigraphic 
imaging of these cells provides information about 
liver size, shape and position. Based on computer- 
simulated images, it has been observed that visual 
assessment of liver function with Tc-colloid is system- 
atically inaccurate, tending to underestimate poor 
function and to overestimate good function (Jago 
et al., 1987). 
On the other hand, the IDA derivatives and I” I- 
rose bengal are taken up by the hepatocyte via an 
anionic pathway in the same manner as bilirubin. 
They provide diagnostic information about the 
patency and the integrity of the biliary drainage 
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system (Chilton and Cowan, 1987). A decrease in 
hepatocellular function with an increase in bilirubin 
level causes a shift from the hepatobiliary excretion 
of these compounds to renal excretion, due to compe- 
tition for uptake with bilirubin. Since these com- 
pounds are taken up and cleared by hepatocytes 
without being metabolized in these cells, they do not 
provide information about the metabolic status of the 
liver. 
Several potential new agents for liver imaging are 
being developed, such as free fatty acid analogs, 
1 5-(p-[‘23 I]iodophenyl)-pentadecanoic acid (IPPA) 
and 17-[‘231]heptadecanoic acid (IHA). In addition to 
being developed clinically as cardiac imaging agents, 
these compounds are also potential hepatic imaging 
agents since they are taken up by the liver via the 
anion uptake mechanism and then metabolized by 
beta oxidation (Machulla and Knust, 1984). Studies 
with IHA in humans have shown that uptake in the 
liver is reduced and the residence time in the liver 
is increased in alcoholic patients with cirrhosis and 
also in patients with diabetes (Mertens et al., 1986; 
Hock et al., 1986). 
The agents described above depend on either 
phagocytosis into reticuloendothelial cells or uptake 
into the hepatocytes via the anionic pathway. 
Alternative means of uptake of radiodiagnostics into 
the liver utilizing receptor binding have also been 
tested. Technitium-99m galactosyl-neoglycoalbumin 
is such an agent. This compound has been shown to 
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bind to a receptor on the cell surface of hepatocytes 
(Vera et al., 1985). In addition, radioscintigraphic 
imaging has also been attempted using ‘231-labeled 
very low density lipoprotein (VLDL) for uptake in 
the liver via the lipoprotein receptor (Huettinger 
et al., 1984). It was shown that 32% of the dose was 
taken up in the liver in the normal rabbit. This uptake 
was decreased when the low density lipoprotein 
(LDL) receptors were down-regulated with choles- 
terol feeding or absent as in the Watanabe-heritable 
hyperlipidemic rabbit. The difficulty with using such 
a technique in humans, however, is that the num- 
ber of liver LDL receptors in the human is much 
lower than that in rabbits, and the clearance rate of 
labeled VLDL from the plasma is much slower. In 
addition, the ‘23I label on the surface apoproteins is 
susceptible to deiodination in viuo. 
It has been previously demonstrated in this labora- 
tory that intravenous administration of radioiodin- 
ated cholesteryl iopanoate solubilized in a detergent 
vehicle readily associated with plasma lipoproteins in 
the rat. At 30 min following injection, approx. 31% 
of the radioactivity accumulated in the liver, and this 
concentration was seen to increase with time. Upon 
incorporation of this compound into chylomicron 
remnants, this uptake was enhanced to 87% present 
in the liver by 30 min (Damle et al., 1983). The 
difficulties with such a preparation are 2-fold. First, 
the efficiency of incorportation of the radiolabeled 
compound into the lipoprotein was very low. Sec- 
ondly, this compound has been shown to be resistant 
to hydrolysis, so it would provide no information 
about the metabolic status of the liver. 
The rationale for the present study is based upon 
our current understanding of mammalian lipoprotein 
metabolism in the liver. The plasma lipoproteins are 
microscopic vesicles that transport the bulk of non- 
polar lipids in the form of a microemulsion, com- 
prised of phospholipids as principal emulsifiers, and 
amphipathic proteins called apoproteins associated 
with the surface of these particles. These apoproteins 
function mainly as ligands for cell-surface receptors. 
The triglyceride-enriched lipoproteins, chylomicrons 
(CM) and very low density lipoproteins (VLDL), are 
synthesized in the intestine and the liver, respectively. 
Once in the circulation, much of the triglyceride is 
hydrolyzed by lipoprotein lipase (LPL) bound by 
heparin sulfate to the endothelial surface of capil- 
laries present in peripheral tissues. The resulting 
smaller, remnant particle exchanges apoproteins and 
is then rapidly taken up in the liver by receptor- 
mediated endocytosis. Hepatic lipase (HL), an 
enzyme bound by heparan sulfate to the endothelial 
cells of the liver, facilitates the uptake of the remnant 
particle by the liver (Sultan et al., 1990). In a num- 
ber of disease states, including alcoholism and dia- 
betes, liver lipoprotein metabolism and HL activity 
are compromised. 
The purpose of this study was to evaluate 
the potential of glycerol-2-palmitoyl-1,3-di(p-iodo- 
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Fig. 1. Structures of 15-(p-iodophenyl)pentadecanoic acid 
(IPPA) and glycerol-2-palmitoyl-1,3-di-15-(p-iodophenyl)- 
pentadecanoate (DPPG). 
phenyl)pentadecanoate (DPPG) as a functional hep- 
atic radiodiagnostic agent. This was accomplished by 
examining its uptake and clearance in normal and 
disease states. This compound would presumably 
be treated as an endogenous triglyceride, becoming 
associated with lipoprotein particles that could be 
taken up in the liver by specific receptors. Once 
taken up by the liver, it could become a substrate 
for liver lipases which would release IPPA for further 
metabolism and excretion. 
Materials and Methods 
Female Sprague-Dawley rats, 20&250 g (Charles 
River, Portage, Mich.) were used in all studies. Rats 
were housed in a temperature and light-controlled 
room. Rats had free access to food and water. 
Diabetes was induced by the injection of streptozo- 
tocin (Sigma, St Louis, MO.) iv. in 0.1 M citrate 
buffer (pH = 4.5) at a dose of 65 mg/kg body wt 3 
days prior to administration of compound (Normura 
et al., 1982). Another group of rats was innoculated 
with Walker 256 carcinoma minced in saline (I g 
tumor/IO mL of saline, I mL injected per rat, > IO6 
cells) in the left hindlimb. These animals were used 
7-10 days later when the tumor weight averaged 10 g. 
An additional group of rats was injected with hep- 
arin, 100 U/kg body wt i.v. IOmin prior to use 
(Gibson et al., 1984). 
Compounds 
Synthesis and radiolabeling. 15-(p -Iodophenyl)- 
pentadecanoic acid (IPPA) was obtained commer- 
cially (Mara Specialty Chemicals, Philadelphia, 
Pa). Glycerol-2-palmitoyl-I ,3-di- 15-(4_iodophenyl)- 
pentadecanoate (DPPG) was synthesized by the fol- 
lowing method: dicyclohexylcarbodiimide (95 mg, 
0.46 mmol) was added to a rapidly stirring solution 
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of 2-monopalmitin (Weichert et al., 1986a) (66mg, 
0.20 mmol), IPPA (186 mg, 0.42 mmol) and a cata- 
lytic amount of dimethylaminopyridine (8 mg) in 
anhydrous CH,Cl, (3 mL) under Nz. The reaction 
mixture was stirred for 48 h, diluted with CH,Cl, 
(10 mL) and filtered to remove precipitated dicyclo- 
hexylurea. The filtrate was washed successively with 
0.5 N HCl (2 x ), saturated aqueous NaHCO, (2 x ), 
H,O, brine and dried (MgS04). Removal of solvent 
in vacua afforded a white residue which was purified 
by column chromatography on silica gel eluted with 
hexanes/ethyl acetate (5 : 2). Combination of the 
appropriate fractions and removal of solvent in vacua 
gave a solid (m.p. 4748°C) which was crystallized 
from acetone to give the title compound: yield 147 mg 
(62%); m.p. Xl-51°C; HPLC (IBM 5 pm silica gel 
column, 10% EtOAc/Hex) K’ = 0.36; TLC (silica 
gel, 28% EtOAc/Hex) R, = 0.61. Analysis calculated 
for (C,,H,,I,O,): C, 61.92; H, 8.52; I, 21.45. Found: 
C, 62.03; H, 8.56; I, 21.35. IPPA and DPPG were 
both radiolabeled with izs I (Amersham, Arlington 
Heights, Ill.) by the pivalic acid melt procedure 
(Weichert et al., 1986b) for tissue distribution studies 
and rat scanning studies. In addition, DPPG was 
radiolabeled with lz31 (Atomic Energy of Canada 
Limited, Vancouver, B.C.) by the same procedure for 
the imaging studies in the dog. 
Formulation. For administration, IPPA was dis- 
solved in ethanol, then 2% bovine serum albumin 
(BSA) in water was added to a final ethanol concen- 
tration of 10%. DPPG was dissolved in hexane or 
benzene and Tween 20 (polyoxyethylene sorbitan 
monolaurate) was added (0.1 mL/mg of compound), 
and the solvent evaporated under a stream of nitro- 
gen with gentle heating. Physiological saline was 
added to give a final Tween 20 concentration of 
l-3%. Any remaining solvent was then evaporated 
until the solution cleared. Both formulated com- 
pounds were extruded through 0.22pm Millex HV 
filters (Millipore, Bedford, Mass.) prior to adminis- 
tration to animals. Prior to use, the compounds 
were assayed for radioactivity using a Searle 1185 
y-counter (84-86% counting efficiency for 12’I). 
Radiochemical purity was assessed by thin layer 
chromatography (TLC) using hexanes : ethyl acetate 
(5 : 2, v/v) for DPPG and methylene chloride: 
methanol (95 : 5, v/v) for IPPA. In all cases, greater 
than 95% of the radioactivity comigrated with the 
standard. 
Tissue distribution. Rats were lightly anes- 
thetized with ether prior to intravenous adminis- 
tration of radiolabeled compound (3.4-18.1 PCi, 
0.009-0.075 pmol). At 5,30,60 min or 24 h following 
administration, the rats were again anesthetized and 
sacrificed by cardiac puncture. Blood was collected 
in a vacutainer tube containing heparin. Blood 
samples were taken for counting and the blood was 
centrifuged at 800 g for 10 min to obtain plasma. The 
following organs were removed, rinsed of blood and 
blotted dry: adrenal, fat, heart, kidney, liver, lung, 
NMB 19/6--C 
muscle, ovary, spleen, thyroid and tumor (where 
applicable). Whole organ weights were taken of liver, 
spleen and tumor. Large organs were minced with 
scissors and portions taken for weighing. All tissue 
samples were weighed in tared cellulose acetate cap- 
sules and then assayed for radioactivity. Results are 
expressed as % administered dose/g tissue and as % 
administered dose/organ. 
Polyacrlyamide gel electrophoresis (PAGE). Plasma 
samples were analyzed (Narayan, 1975) to determine 
the association of radioactivity with plasma proteins 
and lipoproteins. Gels were run and cut as described 
previously (Counsel1 et al., 1989). 
Lipid extraction. Samples of liver and plasma were 
homogenized in chloroform : methanol (Folch et al., 
1957). Following homogenization and extraction, the 
organic phase was analyzed by TLC developed in 
either hexanes:ethyl acetate (5:2, v/v) for DPPG or 
methylene chloride: methanol (95 : 5, v/v) for IPPA. 
TLC results are expressed as the % of total radio- 
activity comigrating with an unlabeled standard of 
either free acid or the triglyceride ester. 
Biochemical assays. To verify the validity of the 
various animal models of liver dysfunction utilized 
in this study, biochemical parameters were measured 
in rats from all treatment groups. Plasma glucose, 
triglyceride, protein and SGOT were determined 
using kits from Sigma (St Louis, MO.), and 
total cholesterol was determined with a kit from 
Worthington (Freehold, N.J.). 
Heparin-releasable hepatic lipase (HL) was 
measured using liver homogenates incubated with 
heparin (Persson and Nilsson-Ehle, 1990). These 
samples were assayed for lipase activity (Nilsson- 
Ehle and Eckman, 1977). Results are expressed as 
nanomoles fatty acid released per hour. 
Gamma camera imaging 
Rats with [‘251]DPPG. Scanning of rats was done 
with an Ohio Nuclear Mobile Camera, using a high 
sensitivity-low energy collimator. Rats were sedated 
with 87 mg/kg ketamine and 13 mg/kg xylazine, 
i.m., positioned supine on the inverted camera 
face, then injected with compound (28.8-53.9 PCi, 
0.1354.324 pmol). Images were accumulated at 
intervals out to 90min following administration of 
compound. Next, animals were injected with 99mTc- 
microaggregated albumin (Microlite, DuPont-NEN 
Medical Products, Boston, Mass.) and an image 
accumulated without shifting the position of the 
animal. Region-of-interest calculations were later 
performed by drawing a 15 x 15 pixel square over the 
99mTc liver image. Another square was drawn over the 
heart to measure blood pool activity. The accumu- 
lated radioactivity in these regions in all scans was 
determined to give the percent of total activity and 
plotted as a function of time. 
Dog with [‘“I]DPPG. A female mongrel dog 
weighing 40 kg was sedated with pentobarbitol for 
the course of the imaging experiment. The dog 
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Table I. Tissue distribution of DPPG in the rat 
5 min 30 min 60 min 24 h 
Tissue (n = 4) (n = 4) (n = 3) (n = 3) 
Adrenal 3.51 + 0.24’ 2.86 0.1 I f I .98 0.40 k I .57 0.07 * 
Blood 1.20*0.12 2.08 k 0.17 I.16 0.26 * 0.12~0.03 
Fat 0.28 f 0.06 0.66 * 0.13 0.26 0.03 k 0.46 0.07 f 
Heart I .35 + 0.09 I .46 0.06 i 0.75 0.18 f 0.09 0.02 + 
Kidney 0.70 i 0.08 0.71 f 0.03 0.59 t 0.08 0.14 * 0.01 
Liver 7.04 rt 0.26 4.16+0.15 1.46 0.37 f 0.24 0.03 + 
Lung 4.62 f 0.34 3.46kO.17 1.22 f 0.68 1.31 * 0.07 
Muscle 0.13 kO.01 0.16kO.02 0.13 * 0.04 0.05 0.00 + 
Ovary I.12 i 0.16 1.03 + 0.03 1.05 i 0.18 0.48 _+ 0.12 
Sp1W.n 0.94 * 0.05 0.86 f 0.04 0.43 f 0.07 0.09 * 0.01 
Thyroid 2.33 f 0.41 14.13 f 1.96 176.8 f 59.0 175.7 + 19.5 
*Results expressed as mean % administered dose per gram tissue + SEM 
received, intravenously, 2.5 mCi [‘231]DPPG forrnu- 
lated in Tween-saline. Images were accumulated on 
a Picker Dyna 4/15 Gamma Camera out to 90 min 
post-injection. At this time a dose of 99mTc-micro- 
aggregated albumin was administered and an image 
accumulated. Region-of-interest accumulations were 
determined as described above. 
Results and Discussion 
Comparison of DPPG to triolein and tripalmitin as a 
substrate for HL 
DPPG was compared to radiolabeled triolein and 
tripalmitin as a substrate for HL. While triolein had 
a greater V_ than both tripalmitin and DPPG 
with values of 34.84, 8.34 and 11.64 nmol/h, respect- 
ively, the K,,, values were 370.37 nmol for triolein, 
312.50 nmol for tripalmitin and 400 nmol for DPPG. 
This indicates that DPPG is similar to tripalmitin as 
a substrate for this enzyme, but is not as good a 
substrate as triolein. These results appear to agree 
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Fig. 2. Uptake of either IPPA or DPPG in the blood and 
liver of the rat at various times post-injection. Results are 
expressed as the mean percent dose taken up per whole 
organ f SEM, n = 34 animals per time point. 
when triolein was used as a substrate compared to 
tripalmitin for either LPL (Wang et al., 1982) or HL 
(Masuno and Okuda, 1986). 
Uptake of DPPG and IPPA in untreated rats 
DPPG administered to untreated rats showed the 
pattern of uptake seen in Table 1. The maximum liver 
uptake was seen at 5 min and corresponded to 52% 
of the administered dose (Fig. 2). While the free fatty 
acid is known to accumulate in the heart, this is not 
seen with administration of the triglyceride even at 1 
or 2 min following administration of the compound 
(results not shown). The increasing levels of activity 
seen in the thyroid with time indicate that metabolism 
and deiodination of the compound are occurring 
within 30 min following administration. 
Similar to DPPG, rats given IPPA showed the 
greatest level of radioactivity in the liver at 5 min 
(Fig. 2). However, this value was approximately one 
half that seen for DPPG. The levels of radioactivity 
in the blood following administration of IPPA were 
similar to that seen for DPPG over the same time- 
course (Fig. 2). 
As can be seen in Table 2, distribution of radioac- 
tivity in the various plasma compartments for the rats 
given IPPA was found to differ significantly from that 
of rats given DPPG. PAGE analysis revealed most of 
the radioactivity (75%) was associated with the albu- 
min fraction following administration of IPPA, indi- 
cating that most of the radioactivity was still present 
as the free fatty acid. On the other hand, DPPG 
administration resulted in greater than 50% of the 
radioactivity associated with lipoproteins by 5 min. 
Table 2. Polyacrylamide gel electrophoresis (PAGE) 
of plasma samples from rats administered either 
IPPA or DPPG at 5 min post-injection 
IPPA DPPG 
(n = 3) (n = 4) 
Stacking gel 3.6 i 0.7+ 6.3 f 2.1 
LDL I.2 * 0.2+* 14.8 + 2.4 
HDL 13.9f8.1’ 35.1 * 1.9 
Albumin 75.0 k 9.6. 37.0 * 5. I 
Below albumin 6.3 * 1.0 6.7 f 2.5 
l P < 0.05 vs rats administered DPPG; **P < 0.01 
vs rats administered DPPG. 
tResults expressed as mean percent of total radio- 
activity applied to gel f SEM. 


























Fig. 3. (a) Lipid extraction of liver and plasma from rats given either IPPA or DPPG at 5 min 
post-injection. Results are expressed as the mean percent of radioactivity extractable into the organic 
phase k SEM for n = 34 animals. (b) TLC of the organic phase extract from these animals. Results are 
expressed as the mean percent of total radioactivity that comigrated either with the free acid or with the 
tryglyceride ester k SEM for n = 34 animals. 
However, an additional 37% of the plasma radioac- 
tivity was found in the albumin fraction, suggesting 
that some hydrolysis of the radiolabeled triglyceride 
had occurred. With time, the percent radioactivity 
associated with the albumin band increased. 
As can be seen in Fig. 3, analysis of the liver 
extraction following administration of IPPA revealed 
that over 66% of the lipid extractable radioactivity 
was in an esterified form (TLC migration was similar 
to that of triglyceride and cholesteryl esters) and far 
exceeded that present as the free acid. It therefore 
appears that IPPA was rapidly esterified upon entry 
into the liver. On the other hand, TLC analysis of the 
radioactivity in the plasma showed the IPPA to be 
largely present as the free fatty acid. The predomi- 
nant form of radioactivity in the liver following 
DPPG administration was the esterified form and 
these esters gave rise to the free acid with time. 
Similarly, at early times radioactivity extracted from 
the plasma of rats receiving DPPG was primarily in 
the triglyceride fraction. This decreased with time, 
concurring with the decreased fraction of radioac- 
tivity seen migrating with lipoproteins on PAGE 
analysis. 
Comparison of animal models 
In order to determine whether the uptake seen in 
normal animals would be altered in disease states, 
animal models with disrupted liver function and 
altered lipoprotein metabolism were studied. These 
included streptozotocin-induced diabetic rats, rats 
bearing a Walker 256 tumor implanted in the thigh 
and rats pretreated with heparin. 
Human type I diabetics have been reported to have 
an increased serum total triglyceride level, especially 
VLDL triglyceride. This is thought both to be due 
to increased synthesis of VLDL in the liver and 
decreased clearance. This decreased clearance is due 
to decreases in adipose and muscle LPL, causing 
decreased removal of triglyceride, and an increasing 
plasma r,,, of the VLDL particle. In addition, dia- 
betic rats have been shown to secrete VLDL lacking 
apoE and apoC (Berry et al., 1981). Also, it has been 
suggested that the apoproteins in diabetics have 
increased glycosylation, reducing their recognition by 
receptors. 
The presence of tumors in humans and experimen- 
tal animals has been widely reported to be associated 
with an increase in plasma triglyceride levels and 
alterations in the lipoproteins, especially an increase 
in VLDL. This increase in VLDL triglyceride is 
thought to be due to decreased lipolysis by LPL. It 
has been demonstrated that tumor necrosis factor 
(also known as cachetin) is secreted by activated 
macrophages, and causes a suppression of LPL 
activity by decreasing the synthesis of the enzyme in 
Table 3. Anatomical and biochemical factors of the rat treatment groups 
Streptozotocin- Tumor- Heparin- 
Treatment group Control diabetic bearing treated 
Organ weight (g) (n = 14) (n = IS) (n = 13) (n = 12) 
Liver 7.37 f 0.137 5.88 + 0.15** 8.96 +_ 0.33*** 1.28 + 0.26 
Spleen 0.46 + 0.02 0.45 * 0.03 1.14 f 0.07*** 0.44 + 0.01 
Glucose (mg/dL)f 151 f 2 486 f 26’. 168 f I5 162+5 
Triglyceride (mg/dL) 70 + 5 186 k 48. 73 + 20 28 f 2** 
Cholesterol (mg/dL) 68 * 3 77 * 5 76 f 4 67 f 6 
SGOT (U/mL) 34 f 2 57 + 4** 81 + S** 36 f 4 
l P < 0.05 vs control rats; l *P < 0.01 vs control rats; ***P < 0.001 vs control rats. 
tResults expressed as mean Jo SEM. 
Sn = 5-6 for all groups for measurement of plasma glucose, triglyceride, cholesterol and SGOT. 
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adipose tissue (Beutler and Cerami, 1987). Along 
with the decrease in LPL activity in adipose, it has 
been demonstrated that LPL activity was increased in 
heart and tumor, leading to an overall increase in 
post-heparin plasma LPL in mice bearing Ehrlich 
ascites tumor (Balint and Holtzinger, 1984). This 
increase in LPL activity in post-heparin plasma, 
along with a decrease in HL activity, has also been 
reported in patients with a variety of cancers, includ- 
ing stomach, lung and pancreas, among others, either 
with or without metastasis to the liver (Masuno and 
Okuda, 1985). 
Initially, certain physical and biochemical par- 
ameters were measured. As can be seen in Table 3, the 
weight of the liver was significantly decreased in the 
Administration of heparin can also alter lipo- 
protein metabolism as both LPL and HL are bound 
to the endothelial surface by heparin sulfate. These 
enzymes are released into the circulation upon treat- 
ment with heparin, by non-specifically binding to the 
polysaccharide. It has been demonstrated that admin- 
istration of heparin in humans results in a reduction 
of the total plasma triglyceride, cholesterol and 
phospholipid. This is due to increased catabolism of 
triglyceride-rich lipoproteins, decreasing VLDL 
cholesterol, protein and triglyceride by 50% and 
increasing LDL and HDL protein and cholesterol 
levels (Aviram et al., 1986). Modifications of the 
lipoprotein patterns seen in normal controls given 
heparin are similar to those seen in early stage chronic 
alcoholics (without administration of heparin) (Sass0 
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Fig. 4. Heparin-releasable hepatic lipase levels in different 
rat treatment groups. Results are expressed as the mean 
nanomoles of fatty acid released per hour + SEM, n = 3. 
diabetic rats, while their spleen weight remained 
similar to control. The tumor-bearing rats showed 
In addition to these anatomical changes, differ- 
both an increased liver and spleen weight. This 
ences in biochemical parameters were observed in 
increase in liver size in the presence of Walker 256 
tumor has been previously noted, however it was also 
these animal models. The streptozotocin-diabetic rats 
reported that the weight of the liver expressed as the 
% of non-tumorous body weight correlated with the 
tumor weight (Tayek et al., 1986). There was no 
difference from control rats in liver or spleen weight 
for the heparin-treated group as would be expected 
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Fig. 5. Uptake of radioactivity in the blood and liver of treated rats at various times post-injection. Results 
are expressed as the mean percent dose taken up per whole organ f SEM, n = 34. 
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Table 4. Polyacrylamide gel electropboresis (PAGE) of plasma samples from different 
treatment groups at 5 min following administration of DPPG 
Streptozotocin- Tumor- Heparin- 
Control diabetic bearing treated 
(n = 4) (n = 3) (n = 3) (n = 3) 
Stacking gel 6.3 f 2.lt 6.6 f 4.3 4.8 f 1.3 9.4 + 0.8 
LDL 14.8 f 2.4 23.1 + 3.0 24.4 + 2.4. 7.2 f 0.6. 
HDL 35.1 * 1.9 44.9 + 2.3’ 35.7 f 3.9 33.0 * 5.1 
Albumin 37.0 + 5.1 14.5 * 0.7. 22.3 f I .7 45.9 * 5.5 
Below albumin 6.7 + 2.5 I I .O f 2.7 12.8 f 1.5 4.3 + 0.6 
l f < 0.05 vs control rats. 
tResults expressed as mean percent of total radioactivity applied to gel k SEM 
showed a 3-fold increase in plasma glucose over 
normal animals. This treatment group also had more 
than double the plasma triglyceride of control, while 
the heparin-treated group had a 3-fold decrease. The 
triglyceride levels of the tumor-bearing animals fell 
over a wide range of values, however, no correlation 
could be found between plasma triglyceride levels and 
the size of each animal’s tumor. Plasma protein and 
cholesterol levels were similar for all treatment 
groups. SGOT levels showed a significant increase in 
the diabetic group and was more than doubled in 
tumor-bearing rats, indicating hepatocellular injury. 
As can be seen in Fig. 4, there were also significantly 
lower HL activities of both the streptozotocin-dia- 
betic and tumor-bearing rats when compared with the 
control animals. 
These changes in diabetic animals at 3 days after 
administration of streptozotocin are in agreement 
with many reports for this animal model (Takanashi 
ef al., 1987). Some investigators have reported a 
moderate hypercholesterolemia in addition to the 
pronounced hypertriglyceridemia (Redgrave and 
Snibson, 1977; Brown et al., 1967). The changes 
seen in the tumor-bearing animals were also in agree- 
ment with the reported hypertriglyceridemia and 
decreased LPL and HL activity seen with a variety 
of tumors (Masuno et al., 1985). In addition, the 
hypotriglyceridemia present in the heparin-treated 
rats was as expected (Sass0 et al., 1985). 
Comparison of tissue disposition of DPPG in different 
animal models 
Each of the three treatment groups showed signifi- 
cantly lower uptake of radioactivity in the liver at 
both 5 and 30min, following administration of 
DPPG (Fig. 5). By 60 min the liver values for each 
group were not significantly different. Both the dia- 
betic and tumored rats showed increased blood levels 
of radioactivity at 5 min, but all three treatment 
groups showed significantly decreased blood levels at 
30 min. At early time periods, the liver radioactivity 
in the diabetic group was significantly lower than the 
blood levels. This is in good agreement with reports 
of the uptake of radiolabeled triglyceride incorpor- 
ated into lipoproteins prior to administration to rats 
(Redgrave and Snibson, 1967; Levy et al., 1985; 
Bar-On et al., 1984). 
The decreased uptake in the fat, heart and liver of 
the tumor-bearing rats corresponds to the decreased 
LPL and HL activity in these animals. Interestingly, 
the tumor does not take up much of the radioactivity 
associated with DPPG, although Walker 256 cells 
have been reported to have LPL activity (Kralovic 
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Fig. 6. (a) Lipid extraction of liver and plasma from treated rats given DPPG at 5 min post-injection. 
Results are expressed as the mean percent of radioactivity extractable into the organic phase f SEM for 
n = 3-4 animals. (b) TLC of the organic phase extract from these animals. Results are expressed as the 
mean percent of total radioactivity that comigrated either with the free acid or with the triglyceride 
ester f SEM for n = 3-4 animals. 
Extraction (b) TLC 
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plasma VLDL triglyceride removal was decreased in 
tumor-bearing mice, with a small accumulation in the 
tumor due to VLDL triglyceride (Lyon et al., 1982). 
When the distribution of radioactivity in the 
plasma was analyzed (Table 4), the diabetic group 
showed more radioactivity in the HDL fraction and 
less in the albumin fraction than control animals at 
5 min. This change in PAGE profile was also seen at 
30 and 60min. The banding pattern seen in tumor- 
bearing animals was not significantly different from 
control rats except for an increase in the radio- 
activity comigrating with LDL. Conversely, heparin- 
treated rats demonstrated a significant decrease in 
LDL-associated activity at 5 min. 
Figure 6 illustrates the results obtained from 
lipid extraction of liver and plasma along with 
TLC analysis of the extract. At early time periods, 
all treatment groups displayed decreased levels 
of extractable activity in the liver. However, the 
percentage of this extractable radioactivity that 
migrated with DPPG on TLC was not significantly 
different for all groups. 
Similar analysis of the plasma revealed that the 
levels of lipid extractable radioactivity were signifi- 
cantly higher for the diabetic and tumored animals at 
5 min. Moreover, the predominant form of this radio- 
activity comigrated with DPPG. However, much less 
activity remained in the esterified form in the heparin- 
treated animals. In this group there was a decrease in 
lipid extractable radioactivity with time. 
Gamma camera scintigraphy of [“jI]DPPG in 
untreated and diabetic rats 
Comparison of the image obtained 15 min follow- 
ing administration of DPPG to an untreated rat 
(Fig. 7) with that obtained with 99mTc demonstrated 
good agreement in the general shape of the liver. 
Radioactivity was observed to clear from the left 
lobes of the liver into the right side, indicating 
clearance of activity into the GI tract with time. This 
was verified by sacrificing the animal while still in 
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Fig. 8. Comparison of the uptake in regions of interest of 
images obtained by y-camera scintigraphy of 1251-labeled 
DPPG administered either to normal or diabetic rats. The 
regions of interest were obtained by placing a 15 x IS pixel 
cursor over the central region of the liver as determined by 
the *Tc image and another cursor over the heart region. 
The results are expressed as the percent of total radioactivity 
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Fig. IO. Comparison of the uptake in regions of interest of 
images obtained by y-camera scintigraphy of ‘231-labeled 
DPPG administered to the dog. The regions of interest were 
obtained by placing a 15 x I5 pixel cursor over the central 
region of the liver as determined by the %Tc image and 
another cursor over the heart region. The results are ex- 
pressed as the percent of total radioactivity in the image 
present in the area of each cursor. 
position on the camera, removing the liver but leav- 
ing the GI tract intact, and rescanning the animal. In 
addition, if the GI tract was removed and placed on 
the camera without the rat, the intestine, particularly 
that section of the duodenum proximal to the 
stomach was visualized (results not shown). Thus, the 
radioactivity appears to be clearing via the biliary 
tree. It is important to note for this comparison, 
however, that ‘*‘I is a very weak ‘~-emitter (28 keV) 
when compared to 99m Tc (140 keV) which accounts 
for the much sharper image seen with the latter. 
When a diabetic rat was given DPPG and subjected 
to y-camera scintigraphy, it demonstrated decreased 
liver uptake compared to that seen for the untreated 
rat. In addition, it showed a great deal of activity in 
the blood pool for the entire scan time. This activity 
did not clear with time (Fig. 8). 
Gamma camera scintigraphy of[‘“l]DPPG in the dog 
It has been reported that the rat, dog and human 
have similar levels of hepatic lipase (Jansen and 
Hulsmann, 1985). A dog was given DPPG radio- 
labeled with iz31 in a Tween-saline vehicle. As can be 
seen in Fig. 9, uptake of radioactivity occurred in the 
liver at 25 min post-injection, although radioactivity 
remained in the blood. With time, the activity in the 
liver was seen to shift into the gall bladder and gut. 
This uptake and clearance was graphed in Fig. 10. 
The pattern of uptake and clearance was very similar 
to that seen in the rat, although slightly delayed. 
Thus, the radioiodinated triglyceride, DPPG, has 
been shown here to rapidly become associated with 
plasma lipoproteins upon administration. This com- 
pound is rapidly taken up in the liver, and the 
associated radioactivity clears the liver with time. In 
comparing the liver uptake of DPPG with the fatty 
acid, IPPA, twice as much DPPG is taken up in the 
liver versus the IPPA. When DPPG was administered 
to diabetic, tumor-bearing or heparin-treated rats, 
15 min DPPG 90 min DPPG 
Fig. 7. Scans obtained when y-camera scintigraphy was performed on either normal or diabetic rats 
injected with ‘2sI-labeled DPPG at either 15 or 90min post-injection. For comparison of liver anatomy 
and localization, 99”Tc-labeled microaggregated albumin ep”Tc) was given to these same animals at the 
conclusion of the study and an image was obtained. 
Fig. 9. Scans obtained when y-camera scintigraphy was performed on a dog injected with ‘231-labeled 
DPGG at 5, 25, 45 and 120min post-injection. For comparison of liver anatomy and localization, 
99mTc-labeled microaggregated albumin ( -Tc) was given to this same animal at the conclusion of the 
study and an image was obtained. 
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the liver uptake was decreased and the clearance was 
altered. These results were confirmed by y-camera 
scintigraphy. Also, while these animals demonstrated 
alterations in their scintigraphic images with DPPG, 
99mTc-microaggregated albumin images in the same 
animals showed no detectable change in uptake. 
Moreover, DPPG was evaluated and found to be 
a substrate for HL. Those animal groups with 
decreased HL activity also showed a decreased liver 
uptake of DPPG. In addition, y-camera scintigraphy 
with DPPG showed a similar pattern of uptake and 
clearance of radioactivity in the dog. 
These preliminary findings demonstrate that 
DPPG is treated in a manner similar to endogenous 
triglycerides and that a radiolabeled triglyceride 
analog such as that described here could be used to 
non-invasively monitor the status of liver lipid metab- 
olism which is disrupted in a number of disease states. 
Further studies are now in progress to assess the 
value of DPPG as a functional hepatic imaging agent. 
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